Panagora Asset Management’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-50,792
| Closed | -$1.02M | – | 1241 |
|
|
2026
Q1 | $1.02M | Sell |
50,792
-58,599
| -54% | -$944K | ﹤0.01% | 706 |
|
|
2025
Q4 | $1.77M | Sell |
109,391
-87,944
| -45% | -$1.16M | 0.01% | 596 |
|
|
2025
Q3 | $2.4M | Sell |
197,335
-95,258
| -33% | -$1.32M | 0.01% | 483 |
|
|
2025
Q2 | $3.31M | Buy |
292,593
+220,697
| +307% | +$2.7M | 0.01% | 385 |
|
|
2025
Q1 | $830K | Hold |
71,896
| – | – | ﹤0.01% | 699 |
|
|
2024
Q4 | $609K | Buy |
+71,896
| New | +$745K | ﹤0.01% | 783 |
|
|
2023
Q4 | – | Sell |
-22,941
| Closed | -$221K | – | 1260 |
|
|
2023
Q3 | $221K | Sell |
22,941
-3,149
| -12% | -$32.2K | ﹤0.01% | 1151 |
|
|
2023
Q2 | $235K | Sell |
26,090
-20,159
| -44% | -$186K | ﹤0.01% | 1154 |
|
|
2023
Q1 | $364K | Buy |
46,249
+27,381
| +145% | +$204K | ﹤0.01% | 1211 |
|
|
2022
Q4 | $128K | Buy |
+18,868
| New | +$101K | ﹤0.01% | 1402 |
|
|
2021
Q3 | – | Sell |
-278
| Closed | -$7K | – | 2055 |
|
|
2021
Q2 | $7K | Sell |
278
-23
| -8% | -$602 | ﹤0.01% | 2375 |
|
|
2021
Q1 | $8K | Hold |
301
| – | – | ﹤0.01% | 2465 |
|
|
2020
Q4 | $6K | Buy |
+301
| New | +$5.16K | ﹤0.01% | 2417 |
|
|
2017
Q4 | – | Sell |
-2,274
| Closed | -$15K | – | 2324 |
|
|
2017
Q3 | $15K | Buy |
2,274
+1,666
| +274% | +$11.9K | ﹤0.01% | 2212 |
|
|
2017
Q2 | $4K | Buy |
+608
| New | +$4.47K | ﹤0.01% | 2523 |
|
|
2015
Q4 | – | Sell |
-11,518
| Closed | -$576K | – | 2332 |
|
|
2015
Q3 | $576K | Sell |
11,518
-3,279
| -22% | -$280K | ﹤0.01% | 1265 |
|
|
2015
Q2 | $1.48M | Buy |
+14,797
| New | +$1.47M | 0.01% | 924 |
|
Other funds holding KALV
Panagora Asset Management's KALV Position: Q2 2026 in Review
Panagora Asset Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 50,792 shares — an estimated $1.02M sold.
Panagora Asset Management first reported a position in KALV in Q2 2015 and held it in 17 quarters. The position peaked at $3.31M in Q2 2025. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Panagora Asset Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Panagora Asset Management sold 50,792 KalVista Pharmaceuticals shares in Q2 2026, an estimated $1.02M.
- Panagora Asset Management first reported a position in KalVista Pharmaceuticals in Q2 2015 and held it in 17 quarters.
- Panagora Asset Management's KalVista Pharmaceuticals position peaked at $3.31M in Q2 2025.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.